Effects of high-dose itraconazole treatment on lipoproteins in men

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 7, 2007, Pages 377-384

  Schneider, B ^a   Gerdsen, R ^a   Plat, J ^b   Dullens, S ^b   Bjorkhem I ^c   Diczfalusy, U ^c   Neuvonen, P J ^d   Bieber, T ^a   von Bergmann, K ^a   Lütjohann, Dieter ^a  

^a UNIVERSITY OF BONN   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Atherogenic risk index; Azoles; Cholesterol synthesis; CYP3A4

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYITRACONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; CELL STRAIN CACO 2; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SELECTIVITY; ENZYMATIC ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY RESEARCH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; MULTIPLE CYCLE TREATMENT; ONYCHOMYCOSIS; OPEN STUDY; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN SYNTHESIS INHIBITION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34447266897     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45377     Document Type: Article

References (41)

1. Allenmark S, Edebo A, Lindgren K. Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection. J Chromatogr. 1990; 532: 203-206.
2. Boogaerts MA, Maertens J, Van Der Geest R, Bosly A, Michaux JM, Van Hoof A, Cleeren M, Wostenborghs R, De Beule K. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother. 2001; 45: 981-985.
3. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, Wolfe ML, Rudling M, Björkhem I, Angelin B, Mancuso JP, Digenio AG, Rader DJ, Schaefer EJ. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol. 2005; 25: 1057-1064.
4. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 1989; 342: 448-451.
5. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970; 11: 583-595.
6. Cedeno J, Mendoza SG, Velazquez E, Nucete H, Speirs J, Glueck CJ. Effect of ketoconazole on plasma sex hormones, lipids, lipoproteins, and apolipoproteins in hyperandrogenic women. Metabolism. 1990; 39: 511-517.
7. Chong PH, Kezele R, Franklin C. High-density lipoprotein cholesterol and the role of statins. Circ J. 2002; 66: 1037-1044.
8. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TI, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356: 348-359.
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
10. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med. 1989; 321: 1311-1316.
11. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239.
12. Gylling H, Vanhanen H, Miettinen TA. Hypolipidemic effect and mechanism of ketoconazole without and with cholestyramine in familial hypercholesterolemia. Metabolism. 1991; 40: 35-41.
13. Gylling H, Vanhanen H, Miettinen TA. Effects of ketoconazole on cholesterol precursors and low density lipoprotein kinetics in hypercholesterolemia. J Lipid Res. 1993; 34: 59-67.
14. Hersberger M, von Eckardstein A. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport. Handb Exp Pharmacol. 2005; 170: 537-561.
15. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990; 323: 1234-1238.
16. Jensen GB, Hampton J. Early termination of drug trials. Br Med J. 2007; 334: 326.
17. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998; 64: 58-65.
18. Kerridge D. Mode of action of clinically important antifungal drugs. Adv Microb Physiol. 1986; 27: 1-72.
19. King JM, Crouse JR, Terry JG, Morgan TM, Spray BJ, Miller NE. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med. 1994; 97: 323-331.
20. Kiss RS, McManus DC, Franklin V, Tan WL, McKenzie A, Chimini G, Marcel YL. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways. J Biol Chem. 2003; 278: 10119-10127.
21. Klotz U. Pharmacological comparison of the statins. Arzneimittelforschung. 2003; 53: 605-611.
22. Miettinen TA. Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res. 1988; 29: 43-51.
23. Miller M, Bachorik PS, McCrindle BW, Kwiterovich PO Jr. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study. Am J Med. 1993; 94: 7-12.
24. Miller M, Burgan RG, Osterlund L, Segrest JP, Garber DW. A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. Arterioscler Thromb Vasc Biol. 1995; 15: 2151-2156.
25. Murthy S, Born E, Mathur SN, Field FJ. LXR/RXR activation enhances basolateral efflux of cholesterol in Caco-2 cells. J Lipid Res. 2002; 43: 1054-1064.
26. Muuronen A, Kaste M, Nikkila EA, Tolppanen EM. Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study. Br Med J (Clin Res Ed). 1985; 291: 1481-1483.
27. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996; 60:54-61.
28. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998; 63: 332-341.
29. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006; 80: 565-581.
30. Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res. 2001; 42: 1173-1179.
31. Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem. 2000; 275: 34508-34511.
32. Piepponen T, Blomqvist K, Brandt H, Havu V, Hollmen A, Kohtamaki K, Lehtonen L, Turjanmaa K. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother. 1992; 29: 195-205.
33. Pierard GE, Arrese JE, Pierard-Franchimont C. Itraconazole. Exp Opin Pharmacother. 2000; 1: 287-304.
34. Remmel RP, Dombrovskis D, Canafax DM. Assay of itraconazole in leukemic patient plasma by reversed-phase small-bore liquid chromatography. J Chromatogr. 1988; 432: 388-394.
35. Schaefer EJ, Asztalos BF. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol. 2006; 17: 394-398.
36. Schmitt C, Perel Y, Harousseau JL, Lemerle S, Chwetzoff E, le Moing JP, Levron JC. Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob Agents Chemother. 2001; 45: 1561-1564.
37. Schmitz G, Langmann T. Structure, function and regulation of the ABC1 gene product. Curr Opin Lipidol. 2001; 12: 129-140.
38. Stalenhoef AF, Stuyt PM, de Graaf J. Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin. Neth J Med. 1997; 51: 10-15.
39. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007; 27: 257-260.
40. Van Cauteren H, Lampo A, Vandenberghe J, Vanparys P, Coussement W, De Coster R, Marsboom R. Toxicological profile and safety evaluation of antifungal azole derivatives. Mycoses. 1989; 32 (Suppl 1): 60-66.
41. Vanden Bossche H, Willemsens G, Marichal P. Anticandida drugs - the biochemical basis for their activity. Crit Rev Microbiol. 1987; 15: 57-72.